Pituitary tumors are the most common form of intracranial neoplasms.
Their prevalence in autopsy series was reported as 5-20 %. 1 However, clinically relevant pituitary tumors presenting with disturbances of hormonal secretion or mass effect are rare, with an estimated prevalence of 200/1,000,000 and an incidence of 2/100,000 per year. 2 Therefore, they only represent about 10 % of all surgically resected intracranial neoplasms. 3, 4 Their prevalence increases with advancing age: both sexes are affected equally. They can cause a variety of endocrine syndromes and disorders 1 including panhypopituitarism, acromegaly, Cushing's disease, infertility, and visual disturbances. Recently, the diagnosis of pituitary adenomas has increased as a result of the advances in neuroimaging technologies.
Due to endocrine hyperfunction, hormonally active adenomas are usually diagnosed at an earlier stage than hormonally inactive ones, which are mostly diagnosed due to the effect of local pressure exerted by the growing tumor. 5 Based on their size, pituitary adenomas can be divided into microadenomas and macroadenomas, the latter being reserved for adenomas larger than 10 mm in diameter. On the other hand, the first histologic classification of pituitary tumors was based on tinctorial characteristics using hematoxylineosin stains on resected tissue. Tumors were accordingly classified as eosinophilic, basophilic, or chromophobic adenomas 4 and were suggested to be associated with acromegaly, Cushing's syndrome and nonfunctioning 
Case Report
A 25-year-old Middle Eastern female was brought to the outpatient clinic with complaints of right-sided hemiparesis, mild right-sided facial paralysis, aphasia, and a long-standing history of amenorrhea. Her menstrual cycles became irregular 8 years ago and then completely stopped to occur. Her family reported that her hemiparesis started in her right hand 2 weeks ago and progressed into a fully blown hemiplegia within 2 days. On admission, she seemed lethargic and was only able to speak with incomprehensible words, partially able to follow commands on her left side. The visual tests were unable to be performed due to lack of adequate cooperation of the patient. Hyperactive deep tendon reflexes and diminished muscle tone were noted on her right-sided extremities.
Magnetic resonance (MR) imaging of the head showed a lobulated, encapsulated mass lesion, occupying the sella turcica, causing a notable expansion of the sella, extending into the suprasellar cistern and invading both cavernous sinuses (see Figure 1 -A, D). Upward displacement of the optic chiasm and hypothalamus was noted. Also, the left carotid syphon seemed to have a remarkably diminished caliber compared with the right. 
Figure 1: Pre-operational Radiology

Axial (A) and coronal (B) T1-weighted magnetic resonance imaging (MRI). Coronal (C) and sagittal (D) T2-weighted MRI. (E) Sagittal computer tomography (CT). (F) Axial diffusionweighted MRI. MR imaging of the head (A-D) showed a lobulated, encapsulated mass lesion, occupying the sella turcica, causing a notable expansion of the sella, extending into the suprasellar cistern and invading both cavernous sinuses. A large ischemic area with hypointensity on T1-weighted images (A, B) and hyperintensity on both T2-(C, D) and diffusion-weighted (F) images could be observed. Cranial CT (E) revealed a spherical dilation and thinning of the sellar wall in all directions.
US ENDOCRINOLOGY
The sellar lesion showed a cystic expansion to the right and superior aspect, while revealing a solid component with mottled enhancement on the left after gadolinium injection. Left carotid syphon was noted to be under compression due to a pronounced invasion of the left cavernous sinus by the lesion. Also, a large ischemic area with hypointensity on T1-weighted images (see Figure 1 -A, B) and hyperintensity on both T2-(see Figure 1 -C, D) and diffusion-weighted (see Figure 1-F Pink-to-purple chunks of tumor tissue were evacuated from the bottom of the encapsulating cyst, by using pituitary ring curettes. Intraoperative frozen section study of these chunks strongly indicated a pituitary adenoma. The remaining cystic wall was dissected away from both optic nerves and the right carotid artery. Normal pituitary gland and a thinned stalk were noted on the right side of the sella adherent to tumor capsule. However, the capsule was strictly adhered to the left carotid artery and the bottom of the sella. Therefore, the adhered capsule was left in place in order to avoid carotid injury. Following closure, the patient was not extubated and moved to an intensive care unit (ICU) under continuing sedation in order to prevent cerebral revascularization injury. She was extubated the next day and immediate improvement in her hemiparesis was noted. Postop MRI revealed a residual tumor in the left cavernous sinus (see Figure   2 ). Prolactin level was decreased to 605 ng/ml on postop day 1 and she was immediately started on cabergoline. Also, hypothyroidism and hypocortisolemia were noted, which were replaced by levothyroxine and methylprednisolone, respectively. She also developed a transient diabetes insipidus, which spontaneously resolved within 4 days. She was moved out of ICU on postop day 2 and started on physiotherapy sessions.
Histologic examination of the tumor under light microscopy revealed an acidophilic adenoma (see Figure 3 -B) with hyperchromatic eccentric
Figure 3: Histopathology
Original magnification factors and staining techniques are given in parenthesis. A. Pituitary adenoma with extensive hemorrhagic foci were displayed (hematoxylin-eosin [H&E] staining, x100). B. Monotonous adenoma cells displayed hyperchromatic nuclei wrapped by acidophilic cytoplasm with intervening extravasated erythrocytes (H&E staining, x200). C. Adenoma cells exhibited scarce prolactin [PRL] immunoreactivity (immunohistochemistry [IHC] with streptavidin biotinylated complex [SBC] and PRL antibody, x400). D. Adenoma was shown to lack reticulum framework, which is assumed to be a striking feature of pituitary neoplasms (silver impregnating staining, x40). E. Adenoma cells exhibited a low Ki67 labeling index of <1 % (IHC with SBC and Ki67 antibody, x400).
nuclei surrounded by polygonal, abundant cytoplasm. In addition to widespread minute hemorrhages (see Figure 3- Figure 3-D) . Immunohistochemical battery of pituitary endocrine markers, including GH, ACTH, LH/FSH, and TSH were all negative and surprisingly, there was only a scarce PRL immunoreactivity that was less than 20 % (see Figure 3-C) . Methylated O6-methylguanine-DNA methyltransferase (MGMT) reactivity was 10-20 %. Nuclear p53 oncoprotein reactivity was negative. A low Ki67 LI of <1 % was calculated (see Figure 3-E) . No immunoreactivity for pancytokeratin was present.
These immunohistopathologic features were consistent with a sparsely granulated PRL cell adenoma undergoing an extensive pituitary apoplexy.
Therefore, the final diagnosis of sparsely granulated PRL cell adenoma was reported despite very high serum PRL levels.
After the patient was released, cabergoline treatment was continued.
Blood PRL levels were monitored regularly and the values at both month 4 and 7 were 50 ng/ml. MR imaging at 7 months after the operation indicated complete stability (see Figure 4 ). She reported a complete recovery of her motor functions. Nonetheless, we could not find any reports of prolactinomas with sparse PRL expression associated with extreme serum PRL levels. Kovacs et al.
Discussion
proposed that either fully or scarcely, PRL immunoreactive cases might express a specific ultrastructural pattern consistent with lactotropes, such as a rough-surfaced endoplasmic reticulum with Nebenkern formation, prominence of Golgi apparatus, presence of misplaced exocytosis, as well as pleomorphism of secretory granules with a considerable variation of size ranging from 130 to 500 nm in diameter. 10 They also suggested that periadenomatous lactotropes might be oversecreting PRL in a null cell adenoma, which might have been given rise to hyperprolactinemia. 10 In our case, the patient was diagnosed with prolactinoma considering the combined results from MR and CT imaging and high serum PRL levels. While the radiologic tests revealed the size, structure, and location of the tumor, the blood tests confirmed the differential diagnosis as a prolactinoma.
Astoundingly, the immunohistopathologic features revealed a few cells with PRL immunoreactivity and no other hormone expression. Therefore, the patient was considered to have a sparsely granulated PRL cell adenoma. For PRL-secreting pituitary adenomas (or prolactinomas), the size of the tumor usually determines the magnitude of the PRL secretion. 11, 12 For instance, PRL serum levels higher than 200 ng/ml is often accepted as the specific cut-off value for prolactinoma, whereas this value is usually less than 100 ng/ml for the stalk effect caused by other types of parasellar tumors by preventing inhibitory control of dopamine secreted from hypothalamus. 9 An extreme increase in serum PRL concentrations suggests a prolactinoma.
However, with giant prolactinomas, as in our case, radioimmunoassay measurements of serum PRL concentrations might result in falsely low values because of the 'hook' effect phenomenon. 13 The initial serum PRL levels in such cases may be only mildly increased (50-150 g/l). However, the actual concentrations are often measured to be in range of several thousands by the serial dilution method. Therefore, in patients with giant tumors (>3 cm), if the initial serum PRL concentration is moderate, serial dilutions must be performed. This process is clinically important to differentiate patients with prolactinomas from others. 1 Treatment of apoplectic pituitary tumors is generally surgical intervention.
The apoplectic bleeding in our patient resulted in a devastating loss of neurologic functions. Therefore, immediate surgical treatment was performed. However, dopamine agonist therapy is the primary treatment for most prolactin-secreting adenomas, even in patients with suprasellar extension and chiasmal compression. 8, 11 This treatment effectively normalizes the serum PRL concentration in approximately 85 % and shrinks the size of the tumor in approximately 70 % of the patients. Regular followups and careful monitoring of the patients are critical to ensure tumor regression in response to medical therapy. 1 In cases resistant to medical treatment, surgical removal via transsphenoidal or transcranial routes can be considered in the first 3 or 4 months. 14 Surgical approach depends to a large degree on tumor size, its extent, the patient's preference, and the available expertise for the managing surgeon. It should be noted that tumor extensions beyond the sella decreases the success probability of the surgery to less than 50 %. 14 However, experienced surgeons may achieve complete or near-complete adenomectomy, with normalization of serum PRL concentration in 60-70 % of the patients. In 20-50 % of these patients, recurrences may occur over a 10-year period.
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Another option for treatment of adenomas is radiotherapy. Traditional radiotherapy is largely being replaced by gamma knife radiosurgery lately due to its increasing availability. Gamma knife treatment is reserved for patients with microadenomas resistant to medical treatment or with residual tumors following surgery. 
